Mortality among patients with familial hypercholesterolemia: a registry-based study in Norway, 1992-2010

Liv Mundal, Mirza Sarancic, Leiv Ose, Per Ole Iversen, Jens-Kristian Borgan, Marit B Veierød, Trond P Leren, Kjetil Retterstøl, Liv Mundal, Mirza Sarancic, Leiv Ose, Per Ole Iversen, Jens-Kristian Borgan, Marit B Veierød, Trond P Leren, Kjetil Retterstøl

Abstract

Background: Untreated patients with familial hypercholesterolemia are at increased risk of premature cardiovascular death. The primary aim of this study was to investigate whether this is also the case in the statin era.

Methods and results: In this registry-based study, 4688 male and female patients from the Unit for Cardiac and Cardiovascular Genetics (UCCG) Registry with verified molecular genetic diagnosis of familial hypercholesterolemia in the period 1992-2010 were linked to the Norwegian Cause of Death Registry. Standardized mortality ratios and 95% CIs were estimated. There were 113 deaths. Mean age of death was 61.1 years. Cardiovascular disease was the most common cause of death (46.0%), followed by cancer (30.1%). Compared with the Norwegian population, cardiovascular disease mortality was significantly higher in the UCCG Registry in all age groups younger than 70 years (standardized mortality ratio 2.29, 95% CI 1.65 to 3.19 in men and women combined; standardized mortality ratio 2.00, 95% CI 1.32 to 3.04 in men; standardized mortality ratio 3.03, 95% CI 1.76 to 5.21 in women). No significant differences were found in all-cause mortality or cancer mortality.

Conclusions: Despite prescription of lipid-lowering drugs, familial hypercholesterolemia patients still had significantly increased cardiovascular disease mortality compared with the general Norwegian population.

Keywords: cardiovascular diseases; hypercholesterolemia; mortality; registries; statins.

© 2014 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.

References

    1. Toleikyte I, Retterstol K, Leren TP, Iversen PO. Pregnancy outcomes in familial hypercholesterolemia: a registry‐based study. Circulation. 2011; 124:1606-1614.
    1. Goldstein JL, Brown MS. Familial hypercholesterolemia: pathogenesis of a receptor disease. Johns Hopkins Med J. 1978; 143:8-16.
    1. Neil A, Cooper J, Betteridge J, Capps N, McDowell I, Durrington P, Seed M, Humphries SE. Reductions in all‐cause, cancer, and coronary mortality in statin‐treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J. 2008; 29:2625-2633.
    1. Leren TP, Finborud TH, Manshaus TE, Ose L, Berge KE. Diagnosis of familial hypercholesterolemia in general practice using clinical diagnostic criteria or genetic testing as part of cascade genetic screening. Community Genet. 2008; 11:26-35.
    1. Civeira F. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis. 2004; 173:55-68.
    1. Heiberg A, Berg K. The inheritance of hyperlipoproteinaemia with xanthomatosis. A study of 132 kindreds. Clin Genet. 1976; 9:203-233.
    1. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, Wiklund O, Hegele RA, Raal FJ, Defesche JC, Wiegman A, Santos RD, Watts GF, Parhofer KG, Hovingh GK, Kovanen PT, Boileau C, Averna M, Boren J, Bruckert E, Catapano AL, Kuivenhoven JA, Pajukanta P, Ray K, Stalenhoef AF, Stroes E, Taskinen MR, Tybjaerg‐Hansen A. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. Eur Heart J. 2013; 34:3478-3490a.
    1. World Health Organization. Familiar Hypercholesterolaemia (FH). 1999Geneva: Report of a second WHO Consultation
    1. Goldstein JL, Brown MS. The LDL receptor. Arterioscler Thromb Vasc Biol. 2009; 29:431-438.
    1. Sijbrands EJ, Westendorp RG, Defesche JC, de Meier PH, Smelt AH, Kastelein JJ. Mortality over two centuries in large pedigree with familial hypercholesterolaemia: family tree mortality study. BMJ. 2001; 322:1019-1023.
    1. Group SSCobotSBR. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis. 1999; 142:105-112.
    1. Gjertsen F. The Norwegian causes of death registry—an important data source for medical research. Tidsskr Nor Laegeforen. 2002; 122:2551-2554.
    1. International Statistical Classification of Diseases and Related Health Problems 10th revision, ICD‐10. Available from: . Accessed September 20, 2012.
    1. Alfsen GC, Lyckander LG. Does quality control of death certificates in hospitals have an impact on cause of death statistics? Tidsskr Nor Laegeforen. 2013; 133:750-755.
    1. Gulsvik AK, Gulsvik A, Svendsen E, Maehle BO, Thelle DS, Wyller TB. Diagnostic validity of fatal cerebral strokes and coronary deaths in mortality statistics: An autopsy study. Eur J Epidemiol. 2011; 26:221-228.
    1. Laursen L, Pettersen JK, Andersen O. Dødelighed og erhverv. 2001København: Danmarks Statistik
    1. Kirkwood BR, Sterne JAC. Essential Medical Statistics. 2003Malden: Blackwell; 268-270.
    1. Borgan J‐K. Yrke og dødelighet 1960–2000. Rapporter 2009/5, Statistics Norway.
    1. Statistisk Sentralbyrå. Flest menn dør av iskemisk hjertesykdom. Rapport 2011. Available at: . Accessed February 26, 2012.
    1. Bonovas S, Filioussi K, Sitaras NM. Statin use and the risk of prostate cancer: A metaanalysis of 6 randomized clinical trials and 13 observational studies. Int J Cancer. 2008; 123:899-904.
    1. Boudreau DM, Yu O, Johnson J. Statin use and cancer risk: a comprehensive review. Expert Opin Drug Saf. 2010; 9:603-621.
    1. Cauley JA, McTiernan A, Rodabough RJ, LaCroix A, Bauer DC, Margolis KL, Paskett ED, Vitolins MZ, Furberg CD, Chlebowski RT. Statin use and breast cancer: prospective results from the women's health initiative. J Natl Cancer Inst. 2006; 98:700-707.
    1. Hippisley‐Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ. 2010; 340:c2197.
    1. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D, Bax J, Vahanian A, Auricchio A, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Filippatos G, Funck‐Brentano C, Hasdai D, Hoes A, Kearney P, Knuuti J, Kolh P, McDonagh T, Moulin C, Poldermans D, Popescu BA, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vardas P, Widimsky P, Windecker S, Berkenboom G, De Graaf J, Descamps O, Gotcheva N, Griffith K, Guida GF, Gulec S, Henkin Y, Huber K, Kesaniemi YA, Lekakis J, Manolis AJ, Marques‐Vidal P, Masana L, McMurray J, Mendes M, Pagava Z, Pedersen T, Prescott E, Rato Q, Rosano G, Sans S, Stalenhoef A, Tokgozoglu L, Viigimaa M, Wittekoek ME, Zamorano JL. ESC/EAS guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011; 32:1769-1818.
    1. World Health Organization. Adherence to Long‐Term Therapies: Evidence for Action. 2003
    1. Leren TP, Berge KE. Subjects with molecularly defined familial hypercholesterolemia or familial defective apoB‐100 are not being adequately treated. PLoS One. 2011; 6:e16721.
    1. Benn M, Watts GF, Tybjaerg‐Hansen A, Nordestgaard BG. Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol‐lowering medication. J Clin Endocrinol Metab. 2012; 97:3956-3964.
    1. Miettinen OS, Cook EF. Confounding: essence and detection. Am J Epidemiol. 1981; 114:593-603.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner